Among 657 participants, 63 and 127 Asian patients were randomized to amivantamab-chemotherapy (ami-chemo) and chemotherapy arms, respectively. At a 9.5-month median follow-up, ami-chemo demonstrated a 46% reduction in disease progression or death risk compared to chemo, with a median PFS of 6.8 months, aligning with overall trends. Ami-chemo exhibited a higher ORR of 66% versus chemo of 32% and improved median intracranial PFS (12.45 vs 8.5 months). In terms of safety, the adverse event rates in Asian patients mirrored the broader MARIPOSA-2 population, with transient, nonserious neutropenia and thrombocytopenia in the ami-chemo arm, mainly during Cycle 1, associated with low rates of febrile neutropenia and bleeding complications. Moreover, amivantamab-chemotherapy had higher rates of grade ≥3 AEs (79%) and dose modifications versus chemotherapy. The treatment-related AEs leading to discontinuation of amivantamab occurred in 11% of patients. Overall, the safety profile of amivantamab-chemotherapy was consistent with individual agents.

KOL insights

"The promising results from the MARIPOSA-2 study show that by combining RYBREVANT with chemotherapy, both with and without lazertinib, patients achieved longer progression-free survival compared with chemotherapy alone”. –Expert Opinion.

Conclusion

In line with the primary findings of MARIPOSA-2, amivantamab-chemotherapy achieves a significant 46% reduction in progression or mortality among Asian patients, establishing itself as the latest gold standard for treating EGFR-mutated advanced NSCLC following progression on osimertinib.

Note: The therapeutics segment is experiencing significant NSCLC clinical trial activity, which is further expected to drive Non-Small Cell Lung Caner market growth in the coming years.